A novel approach to medical radioisotope production using inverse kinematics: a successful production test of the theranostic radionuclide 67Cu
Authors:
G Souliotis,
M Rodrigues,
K Wang,
V Iacob,
N Nica,
B Roeder,
G Tabacaru,
M Yu,
P Zanotti-Fregonara,
A Bonasera
Abstract:
A novel method for the production of important medical radioisotopes has been developed. The approach is based on performing the nuclear reaction in inverse kinematics, namely sending a heavy-ion beam of appropriate energy on a light target (e.g. H, d, He) and collecting the isotope of interest. In this work, as a proof-of-concept, we studied the production of the theranostic radionuclide 67Cu (T…
▽ More
A novel method for the production of important medical radioisotopes has been developed. The approach is based on performing the nuclear reaction in inverse kinematics, namely sending a heavy-ion beam of appropriate energy on a light target (e.g. H, d, He) and collecting the isotope of interest. In this work, as a proof-of-concept, we studied the production of the theranostic radionuclide 67Cu (T 1/2 =62 h) via the reaction of a 70Zn beam at 15 MeV/nucleon with a hydrogen gas target. The 67Cu radionuclide, alongside other coproduced isotopes, was collected after the gas target on an Al catcher foil and their radioactivity was measured by off-line γ-ray analysis. After 36 h from the end of the irradiation, apart from the product of interest 67Cu, the main radioimpurity coming from the 70Zn+p reaction was 69mZn (T 1/2 =13.8 h) that can be reduced by further radio-cooling. Moreover, along with the radionuclide of interest produced in inverse kinematics, the production of additional radioisotopes is possible by making use of the forward-focused neutrons from the reaction and letting them interact with a secondary target. A preliminary successful test of this concept was realized in the present study. The main requirement to obtain activities appropriate for preclinical studies is the development of high-intensity heavy-ion primary beams.
△ Less
Submitted 4 January, 2019;
originally announced January 2019.
